OX2 Therapeutics Report issue

For profit Phase 1
Founded: palo alto ca United States (2016)

Organization Overview

First Clinical Trial
2020
NCT04642937
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

OX2 Therapeutics

Active Ingredients

Drugs in Phase 1 Trials (1)

hp1a8 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioblastoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1